The lipid accumulation products index as a good predictor of cardiovascular risk in patients with chronic kidney disease in hemodialysis
DOI:
https://doi.org/10.33448/rsd-v11i2.25401Keywords:
Kidney Disease; Dialysis; Anthropometry; Cardiovascular diseases.Abstract
Objective: To evaluate the predictive power of the Lipid Accumulation Products (LAP) index in the identification of cardiovascular risk in patients with kidney disease undergoing hemodialysis compared to traditional anthropometric and biochemical indicators. Methods: cross-sectional study involving 77 patients with Chronic Kidney Disease (CKD) undergoing hemodialysis treatment. Identification data, anthropometry and biochemical measurements were collected. Anthropometric, biochemical and combination of both (LAP) indicators were calculated. A receiver operating characteristic (ROC) curve was performed and the areas under the curve were estimated in order to identify the power of identification of Cardiovascular Risk (CVR) and establish cutoff points for the indicators. Results: Most individuals presented cardiovascular risk according to the Waist-Height Ratio (WHR). Medians of total cholesterol and triglycerides and mean LDL-c were higher in the CVR group assessed by non-HDL cholesterol compared to those without CVR (p<0.05). The LAP score showed significant differences between the CVR groups, with the LAP median being 77.54 (45.72-142.88), higher in the group with CVR compared to those without CVR, 43.06 (30.98- 77.06). LAP (AUC: 0.705; 95%CI: 0.589-0.821; p=0.003) was the best discriminator of RCV, where LAP cutoff point >92.21, sensitivity of 44% and specificity of 92.59% were estimated to identify the RCV. Conclusion: The LAP index showed greater power in identifying the CVR when compared to isolated anthropometric or biochemical measurements.
References
Almeida, A. F., Sena, M. H. L. G., Santana, G. T., Barbosa, R. L., Gobatto, A. L. N., Conceição, M. E. P., et al (2017). Razão TG/HDL-c, indicadores antropométricos e bioquímicos de risco cardiovascular no renal crônico em tratamento conservador. Nutricion Clinica y Dietetica Hospitalaria, 37(4): 10-16.
Associação Brasileira para o Estudo da Obesidade e da Síndrome Metabólica – ABESO (2016). Diretrizes brasileiras de obesidade. Associação Brasileira para o estudo da Obesidade e da Síndrome Metabólica, 4 ed, 4: 1-188.
Bagasrawala, S. I., Sheth, H., Shah, H., Ansari, R., Lakdawala, M (2019). Metabolic Syndrome Rather than Obesity Alone Is More Significant for Kidney Disease. Obes Surg, 29(11):3478-3483. doi: 10.1007/s11695-019-04011-2.
Baigent, C. et al (2011). “The effects of lowering LDL cholesterol with simvastatin plus ezetimibe in patients with chronic kidney disease (Study of Heart and Renal Protection): a randomised placebo-controlled trial.” Lancet (London, England), 377,9784: 2181-92. doi:10.1016/S0140-6736(11)60739-3.
Bartekova, M., Radosinska, J., Jelemensky, M., Dhalla, N. S (2018). Role of cytokines and inflammation in heart function during health and disease. Heart Fail Rev, 23(5):733-758. doi: 10.1007/s10741-018-9716-x.
Biyik, Z., Guney, I (2019). Lipid accumulation product and visceral adiposity ındex: two new indices to predict metabolic syndrome in chronic kidney disease. Eur Rev Med Pharmacol Sci, 23(5):2167-2173. doi: 10.26355/eurrev_201903_17262.
Brandão, H. F. C., Saraiva, M. B. M., Sousa, B. S., Almeida, S. S., Souza, E. D. S., Melo, H. C. M., et al (2021). Estado nutricional e sua associação com risco cardiovascular no paciente em tratamento hemodialítico. Brazilian Journal Of Development, 7(2): 11712-11728.
Brasil - Ministério da Saúde (2011). Orientações para a coleta e análise de dados antropométricos em serviços de saúde: Norma técnica do Sistema de Vigilância Alimentar e Nutricional - SISVAN. Ministério da Saúde, Secretaria de Atenção à Saúde, Departamento de Atenção Básica, Ministério da Saúde, 76p.
Câmara, N. O., Iseki, K., Kramer, H., Liu, Z. H., Sharma, K (2017). Kidney disease and obesity: epidemiology, mechanisms and treatment. Nat Rev Nephrol, 13(3):181-190. doi: 10.1038/nrneph.2016.191. Epub 2017.
Chang, T. I., Streja, E., Ko, G. J., Naderi, N., Rhee, C. M., Kovesdy, C. P. et al (2018). Inverse Association Between Serum Non–High-Density Lipoprotein Cholesterol Levels and Mortality in Patients Undergoing Incident Hemodialysis. J Am Heart Assoc, 7:e009096. DOI: 10.1161/JAHA.118.009096.
Chiu, H., Wu, P. Y., Huang, J. C., Tu, H. P., Lin, M. Y., Chen, S. C. C., Chang, J. M (2020). There is a U shaped association betweem non high densitu lipoprotein cholesterel with overall and cardiovascular mortality in chronic kidney disease stage 3-5. Scientifc Reports, 10(1):1-11.
Conselho Nacional de Saúde (BRASIL). Resolução nº 466, de 12 de dezembro de 2012. Brasília, 2012. Disponível em: http://www.conselho.saude.gov.br/resolucoes/reso_12.htm. Acesso em 27 abr 2021.
D'Agati, V. D., Chagnac, A., de Vries, A. P., Levi, M., Porrini, E., Herman-Edelstein, M., Praga, M (2016). Obesity-related glomerulopathy: clinical and pathologic characteristics and pathogenesis. Nat Rev Nephrol, 12(8):453-71. doi: 10.1038/nrneph.2016.75.
Davies, S. J., Davenport, A (2014). The role of bioimpedance and biomarkers in helping to aid clinical decision-making of volume assessments in dialysis patients. Kidney Int, 86(3):489-96. doi: 10.1038/ki.2014.207.
Greffin, S., André, M. B., Matos, J. P. S., Kang, H. C., Jorge, A. J. L., Rosa, M. L. G., et al (2017). Chronic kidney disease and metabolic syndrome as risk factors for cardiovascular disease in a primary care program. J Bras Nefrologia, 39(3): 246-252.
Guo, S. X., Zhang, X. H., Zhang, J. Y., He, J., Yan, Y. Z., Ma, J. L., Ma, R. L., Guo, H., Mu, L. T., Li, S. G., Niu, Q., Rui, D. S., Zhang, M., Liu, J. M., Wang, K., Xu, S. Z., Gao, X., Ding, Y. S (2016). Visceral Adiposity and Anthropometric Indicators as Screening Tools of Metabolic Syndrome among Low Income Rural Adults in Xinjiang. Sci Rep, 26;6:36091.
Kahn, H. S (2005). The lipid accumulation product performs better tha the body mass index for recognizing cardiovascular risk: a population-based comparison. BMC Cardiovasc Disord. 5(26), doi:10.1186/1471-2261-5-26.
KDIGO (2014). Kidney Disease: Improving Global Outcomes (KDIGO) Lipid Working Group. KDIGO clinical practice guideline for lipid management in chronic kidney disease. Kidney Int. Suppl, 3, 263–305.
Lin, T. Y., Hung, S. C., Lim, P. S (2019). Central obesity and incident atherosclerotic cardiovascular disease events in hemodialysis patients. Nutr Metab Cardiovasc Dis, 9;30(3):500-507. doi: 10.1016/j.numecd.2019.11.004. Epub 2019 Nov 15.
Liu, Y., Wang, Y., Wang, J., Chen, K., Jin, L., Wang, W., Gao, Z., Tang, X., Yan, L., Wan, Q., Luo, Z., Qin, G., Chen, L., Um, Y (2021). Lipid Accumulation Product is Associated with Urinary Albumin-creatinine Ratio in Chinese Prediabitic Population: A Report from the REACTION Study. Diabetes Metab Syndr Obes, 28;14:2415-2425. doi: 10.2147/DMSO.S310751.
Major, R. W., Cheng, M. R. I., Grant, R. A., Shantikumar, S., Xu, G., Oozeerally, I., Brunskill, N. J., Gray, L. J (2018). Cardiovascular disease risk factors in chronic kidney disease: A systematic review and meta-analysis. PLoS One, 21;13(3):e0192895. doi: 10.1371/journal.pone.0192895.
Millan, J., Pinto, X., Munoz, A., Zuniga, M., Rubies-Prat, J., Pallardo, L. F., et al (2009). Lipoprotein ratios: Physiological significance and clinical usefulness in cardiovascular prevention. Vasc Health Risk Manag, 5:757–65.
Ministério da Saúde. Secretaria de Atenção à Saúde. Departamento de Atenção Especializada e Temática. Diretrizes Clínicas para o Cuidado ao paciente com Doença Renal Crônica – DRC no Sistema Único de Saúde. Brasília (Brasil) 2014; 37.
Mondal, E. et al (2021). “The Pattern of Lipid Profile in Patients with Chronic Kidney Disease”. Mymensingh medical journal MMJ, 30(1): 48-55.
Motamed, N., Razmjou, S., Hemmasi, G., Maadi, M., Zamani, F (2015). Lipid accumulation product and metabolic syndrome: a population-based study in northern Iran, Amol. J Endocrinol Invest, 39(4):375-82. doi: 10.1007/s40618-015-0369-5.
Nishi, H., Higashihara, T., Inagi, R (2019). Lipotoxicity in Kidney, Heart, and Skeletal Muscle Dysfunction. Nutrients, 20;11(7):1664. doi: 10.3390/nu11071664. PMID: 31330812.
Pereira-Rodríguez, J. E., Boada-Morales, L., Niño-Serrato, D. R., Caballero-Chavarro, M., Ricón-Gonzalez, G., Jaimes-Martín, T., et al (2017). Síndrome cardiorrenal. Rev Colomb Cardio, 24(6): 602-613.
Précoma, D. B., Oliveira, G. M. M., Simão, A. F., Dutra, O. P., Coelho, O. R., Izar, M. C. O., et al (2019). Updated Cardiovascular Prevention Guideline of the Brazilian Society of Cardiology - 2019. Arq Bras Cardiol, 113(4): 787–891.
Sociedade Brasileira de Cardiologia (2017). Atualização da Diretriz brasileira de dislipidemia e prevenção da aterosclerose. Arquivos Brasileiros de Cardiologia, 109(2):1-92
Sumida, K., Kovesdy, C. P (2019). The gut-kidney-heart axis in chronic kidney disease. Physiol Int, 1;106(3):195-206. doi: 10.1556/2060.106.2019.19. Epub 2019 Sep 27.
Wen, J., Chen, Y., Huang, Y., Lu, Y., Liu, X., Zhou, H., et al (2017). Association of the TG/HDL-C and Non-HDL-C/HDL-C Ratios with Chronic Kidney Disease in an Adult Chinese Population. Kidney And Blood Pressure Research, 42(6):1141-1154.
World Health Organization (1997). Obesity. Preventing and managing the global epidemic. Geneva: report of a WHO consultation on obesity.
Zanoli, L., Lentini, P., Briet, M., Castellino, P., House, A. A., London, G. M., Malatino, L., McCullough, P. A., Mikhailidis, D. P., Boutouyrie, P (2019). Arterial Stiffness in the Heart Disease of CKD. J Am Soc Nephrol, 30(6):918-928. doi: 10.1681/ASN.2019020117. Epub 2019 Apr 30.
Zhang, K., Li, Q., Chen, Y., Wang, N., Lu, Y (2017). Visceral adiposity and renal function: an observational study from SPECT-China. Lipids Health Dis, 27;16(1):205. doi: 10.1186/s12944-017-0597-0.
Zhang, X. H., Zhang, M., He, J., Yan, Y. Z., Ma, J. L., Wang, K., Ma, R. L., Guo, H., Um, L. T., Ding, Y. S., Zhang, J. Y., Liu, J. M., Li, S. G., Niu, Q., Rui, D. S., Guo, S. X (2016). Comparison of Anthropometric and Atherogenic Indices as Screening Tools of Metabolic Syndrome in the Kazakh Adult Population in Xinjiang. Int J Environ Res Public Health, 16;13(4):428. doi: 10.3390/ijerph13040428. PMID: 27092520;
Zou, Y., Sheng, G., Yu, M., Xie, G (2020). The association between triglycerides and ectopic fat obesity: An inverted U-shaped curve. PLoS One, 30;15(11):e0243068. doi: 10.1371/journal.pone.0243068.
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2022 Alexandre Danton Viana Pinheiro; Francisca Isabelle da Silva e Sousa; Dayane Estéfane Barros Albuquerque Linhares; Ribanna Aparecida Marques Braga; Ruth Silva Galdino; Francisco José Maia Pinto; Carla Soraya Costa Maia
This work is licensed under a Creative Commons Attribution 4.0 International License.
Authors who publish with this journal agree to the following terms:
1) Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.
2) Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.
3) Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work.
